WO2019119098A1 - Dispositif ophtalmique à méta-lentille et son procédé de fabrication - Google Patents

Dispositif ophtalmique à méta-lentille et son procédé de fabrication Download PDF

Info

Publication number
WO2019119098A1
WO2019119098A1 PCT/CA2017/051529 CA2017051529W WO2019119098A1 WO 2019119098 A1 WO2019119098 A1 WO 2019119098A1 CA 2017051529 W CA2017051529 W CA 2017051529W WO 2019119098 A1 WO2019119098 A1 WO 2019119098A1
Authority
WO
WIPO (PCT)
Prior art keywords
metalens
ophthalmic device
implant
substrate
subwavelength structures
Prior art date
Application number
PCT/CA2017/051529
Other languages
English (en)
Inventor
Brent MACINNIS
Original Assignee
Macinnis Brent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macinnis Brent filed Critical Macinnis Brent
Priority to PCT/CA2017/051529 priority Critical patent/WO2019119098A1/fr
Priority to CA3083612A priority patent/CA3083612A1/fr
Priority to EP17935708.2A priority patent/EP3727199A4/fr
Publication of WO2019119098A1 publication Critical patent/WO2019119098A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16—Intraocular lenses
    • A61F2/1613—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16—Intraocular lenses
    • A61F2/1613—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
    • A61F2/1648—Multipart lenses
    • A61F2/1651—Multipart lenses comprising a telescope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/002—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of materials engineered to provide properties not available in nature, e.g. metamaterials
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/04—Contact lenses for the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16—Intraocular lenses
    • A61F2002/1681—Intraocular lenses having supporting structure for lens, e.g. haptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G02B1/041—Lenses
    • G02B1/043—Contact lenses
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B2207/00—Coding scheme for general features or characteristics of optical elements and systems of subclass G02B, but not including elements and systems which would be classified in G02B6/00 and subgroups
    • G02B2207/101—Nanooptics

Definitions

  • the present disclosure relates to ophthalmic devices including intraocular lens implants, contact lenses and the like. More particularly, the present disclosure relates to ophthalmic devices including one or more metalenses.
  • Ophthalmic devices are used to treat a variety of eye conditions. Such devices include intraocular lens (IOL) implants, contact lenses, corneal inlays, intraocular telescopes, and the like. Such ophthalmic devices typically include one or more lenses to interact with visible light. For example, a contact lens is placed on the eye to correct an eyesight condition (e.g. near or far-sightedness). An IOL implant is implanted within the eye.
  • IOL intraocular lens
  • An IOL implant may replace the natural lens in the eye, or the natural lens may remain.
  • a phakic IOL implant is implanted in the eye without altering the natural lens of the eye.
  • Ophthalmic devices typically utilize refractive or diffractive lenses.
  • Implanting lOLs is an invasive procedure that requires creating an incision in the eye. Reducing the thickness of lOLs may reduce complications associated therewith. The minimum thickness of a
  • conventional ophthalmic device may be limited by the refractive lens.
  • an ophthalmic device comprising: a biocompatible polymer body; and a metalens encapsulated within the polymer body, the metalens comprising: a substantially transparent substrate; and a plurality of subwavelength structures arranged on the substrate in a pattern to interact with visible light, the subwavelength structures comprising a dielectric material.
  • the device comprises an implant or inlay for an eye.
  • the implant or inlay comprises one of: an intraocular lens implant; and an intracorneal lens inlay.
  • the device comprises the intraocular implant, and the intraocular implant comprises one of: a phakic intraocular lens implant; and a posterior chamber intraocular lens implant.
  • the device comprises a contact lens.
  • the dielectric material is titanium dioxide.
  • the polymer body is hydrophobic.
  • the polymer body comprises one of: acrylic polymer and silicone hydrogel.
  • the plurality of subwavelength structures comprises nanopillars.
  • the substrate comprises a polymer substrate.
  • the polymer substrate is flexible.
  • the polymer substrate comprises at least one of: silicone, acrylic and a hydrogel.
  • the metalens is configured to correct an eyesight condition.
  • the subwavelength structures each have at least one respective dimension that is less than a wavelength of the visible light.
  • the at least one dimension comprises at least one of height, width and thickness of the subwavelength structure.
  • the metalens interacts with the visible light over a range of visible light wavelengths.
  • a method for making an ophthalmic device comprising: providing a metalens comprising a substantially transparent substrate and a plurality of
  • subwavelength structures arranged on the substrate in a pattern to interact with visible light, the subwavelength structures comprising a dielectric material; and encapsulating the metalens in a biocompatible polymer body.
  • providing the metalens comprises fabricating the metalens using an electron beam lithography (EBL) process.
  • EBL electron beam lithography
  • Figure 1 is a front view of an example IOL implant according to some embodiments.
  • Figure 2 is a side view of the IOL implant of Figure 1 ;
  • Figure 3 is an enlarged perspective partial view of an example array of nanofins of a metalens
  • Figure 4 is a side cross-sectional view of a human eye showing example embodiments of ophthalmic devices;
  • Figure 5 is a side perspective view of an ophthalmic device according to another embodiment;
  • Figure 6 is another side perspective view of the ophthalmic device of Figure 5;
  • Figure 7 is a flowchart of a method for making an ophthalmic device according to some embodiments.
  • Figure 8 is a flowchart of a method for making a metalens for an ophthalmic device using an electron beam lithography (EBL) process according to some embodiments.
  • EBL electron beam lithography
  • a conventional ophthalmic device such as an intraocular lens (IOL) implant, intracorneal implant or inlay, or a contact lens, may include a refractive lens to interact with visible light.
  • the minimum thickness of the device may be limited by the geometric requirements of the one or more refractive lenses. It may be desirable to reduce the thickness of such devices.
  • Conventional surgical incisions made by blades or lasers for insertion of an IOL device may have a minimum size that is limited by the lOL’s size, thickness and foldability. Reducing the thickness of the device may consequently reduce the necessary size of the incision in the eye.
  • Reducing the size of the incision and the device may, in turn, reduce trauma to the eye such as scarring and induced astigmatism resulting from surgery.
  • Foldable lenses or IOL implants comprising polymers (e.g. hydrophobic acrylic, silicone, hydrogels etc.) may further reduce the required incision size.
  • a thinner corneal inlay may require a smaller“pocket” to hold it, which may be less disruptive to the normal cornea.
  • reducing the thickness of contact lenses or corneal inlays may result in greater oxygen permeability (dK, dKt) and a healthier cornea.
  • conventional intraocular telescopic housings are relatively large and may require large incisions with sutures to close.
  • a smaller IOL telescope may allow smaller, possibly sutureless incisions, which may result in fewer surgical complications.
  • there is less room since the natural lens is still in place. Reducing the thickness of a phakic IOL implant may provide advantages, regardless of whether the implant is in the anterior chamber, fixed to the iris, or in the posterior chamber sulcus.
  • A“metalens” is a lens including an array of structures on a substrate that interact with electromagnetic radiation.
  • the structures have dimensions that are less than the wavelength(s) of the radiation and are arranged in a pattern which alters an incoming wavefront in a non-refractive, non-diffractive manner by virtue of the composition, shape, orientation, height and diameter of the structures.
  • Structures having such dimensions are referred to herein as“subwavelength structures”.
  • the subwavelength structures To interact with electromagnetic radiation in the visible spectrum (i.e. visible light), the subwavelength structures have dimensions such as height, width and/or spacing in the nanometer range. Thus, such structures may be referred to as nanostructures.
  • Nanostructures may be in the form of nanofins or other nanopillars which act as sub-wavelength light phase shifters rather than traditional lenses.
  • the term“nanopillar” refers to any structure with one or more subwavelength dimensions (height, width, thickness) that extends away from the substrate.
  • the term“nanofin” refers to a nanopillar with a generally fin-like shape.
  • nanofins may have a generally rectangular prism-like shape as shown in Figure 3.
  • a metalens may also be referred to as a“planar lens”.
  • the dimensions of the subwavelength structures may allow a metalens to be much thinner than a refractive lens.
  • a metalens may, thus, be referred to as“nano-thin” or“ultrathin”.
  • Metalenses have been proposed for use in various electronic devices such as cellphone/camera lenses, virtual reality headsets, LED focusing devices, laser lenses, holograms, diffraction gratings, microscope lenses, spectrometers etc. [0037]
  • many conventional metalenses are not suitable for use in ophthalmic devices, which require biocompatibility and may require functioning over a broad range of visible wavelengths. The term
  • biocompatible herein means generally not harmful to living human tissue.
  • Some metalenses have been designed to function in the visible spectrum only at a particular wavelength or in a very narrow wavelength range.
  • Some existing metalenses that do interact with visible light include metal nanostructures. Such metalenses are subject to magnetic attraction and thus unsuited to use in or on the eye.
  • an ophthalmic device comprising a metalens encapsulated in a biocompatible polymer body, such as hydrophobic acrylic body.
  • the metalens comprises a plurality of subwavelength dielectric structures arranged on a substrate to interact with visible light.
  • the substrate may, for example, be a substantially transparent polymer or another light-transmissive material.
  • the dielectric may be titanium dioxide (Ti02).
  • the subwavelength dielectric structures may be nanofins or nanopillars arranged to function over a range of wavelengths.
  • the resulting metalens-based ophthalmic device may be thinner than conventional devices. As discussed above, reducing the thickness of such devices may be advantageous (smaller incision size required, etc.).
  • Example metalens structures including Ti02 nanostructures to interact with visible light over a suitable spectrum range are described by Mohammadreza Khorasaninejad, et al., in“Visible Wavelength Planar Metalenses Based on Titanium Dioxide, IEEE Journal of Selected Topics in Quantum Electronics, Vol. 23, No. 3, May/June 2017, which is incorporated by reference herein in its entirety.
  • Example Ti02-based metalenses are also described by Byrnes et al. in U.S. Patent Application Publication No.
  • the metalenses described herein may be configured to interact with visible light having wavelength in the range of 380 to 660 nm.
  • Mohammadreza Khorasaninejad, et al. show results for Ti02 metalenses at wavelengths of 660nm, 532nm and 405nm and state that the operating bandwidth of such metalenses may be expanded by dispersion engineering to a multi-wavelength regime and potentially for a continuous wavelength range. See also F. Aieta, M.A. Kats, P. Genevet, and F. Capasso, “Multiwavelength Achromatic Metasurfaces by Dispersive Phase
  • Ti02 metalens nanostructures and a hydrophobic acrylic body may provide particular advantages for IOL implants and other ophthalmic devices.
  • Ti02 (and other dielectrics) is non-magnetic and, thus, more suitable for use in an intraocular implant than metal.
  • Ti02 also has been shown to be suitable for metalenses that function over a suitably broad range of the visible light spectrum.
  • Ti02 is also biocompatible and bioinert and has been used in other types of biomedical devices such as dental implants, orthopedic implants, catheters, etc.
  • Ti02 may have negligible optical absorption in the visible spectrum.
  • Other potential benefits of Ti02 include its high index of refraction (close to diamond), high melting point, and antimicrobial properties. See for example, Joseph A.
  • Ti02 when deposited, may be strongly adherent to the substrate and chemically impermeable.
  • hydrophobic acrylic may be a beneficial material for the body that encapsulates the metalens because it is biocompatible and has been shown as safe in conventional ophthalmic devices.
  • a hydrophobic acrylic encapsulating body may be safe and facilitate obtaining regulatory approval.
  • the subwavelength structures of the metalens are not limited to Ti02. In other embodiments, the subwavelength structures may be made of one or more other dielectric materials including, but not limited to, quartz, Gallium Nitride (GaN), and silicon nitride. [0043]
  • the substrate of the metalens may be any suitable
  • substantially light-transmissive or transparent material examples include, but are not limited to, substantially transparent polymer such as silicone, hydrophobic or hydrophilic acrylic, or a hydrogel.
  • the substrate may also be a High Refractive Index Polymer (HRIP) nano-composite material, which may be an organic matrix with high refractive inorganic nanoparticles combined to create a substrate.
  • the substrate may have a chromophore or coating to filter ultraviolet (UV) light to protect the eye from UV exposure.
  • UV ultraviolet
  • the substrate may be substantially rigid in some embodiments.
  • the substrate may be a flexible, bendable material (e.g. silicone, hydrophobic or hydrophilic acrylic, or a hydrogel).
  • a bendable or foldable substrate may provide additional versatility. For example, metalens-based IOL implants that are thin and sufficiently foldable may be rolled and injected into the eye through a cartridge, further reducing incision size.
  • substantially transparent does not require absolute transparency. Rather, for example, a tinted and/or other highly transmissive material may be considered substantially transparent in that it is suitable for use in ophthalmic devices.
  • the polymer body that encapsulates the metalens is not limited to hydrophobic acrylic, and other suitable biocompatible polymer materials may be used.
  • other possible body materials include Silicone Hydrogel (SiHy), polymethylmethacrylate (PMMA), hydrophobic acrylic, hydrophilic acrylic, silicone and collamer.
  • FIG. 1 is a front view of an example IOL implant 100 according to some embodiments.
  • the implant 100 includes a hydrophobic acrylic polymer body 102 and a metalens 104 encapsulated by the body 102.
  • the metalens 104 comprises a polymer substrate 106 with an array of Ti02 subwavelength structures 108 arranged thereon.
  • the subwavelength structures 108 are arranged on the substrate in a pattern to interact with visible light.
  • the metalens 104 in this example is planar disc-shaped having a diameter (d2) of approximately 6 mm (although the diameter may vary in other embodiments).
  • the subwavelength structures 108 are arranged in a pattern that extends radially about a center axis 124 (shown in Figure 2) of the metalens 104 for an iris-like distribution.
  • the metalens in this example defines a circular center area 1 12 that does not include the subwavelength structures.
  • the subwavelength structures 108 are not included in the center area 1 12 in this embodiment because axial and paraxial rays passing therethrough may not require refraction to focus.
  • the center area 1 12 has a diameter (d3) of approximately 2 mm, although embodiments are not limited to this dimension. In other embodiments, the center area 1 12 may be larger or smaller.
  • the metalens 104 may include subwavelength structures in the region occupied by the center area 1 12 in Figure 1 .
  • the body 102 is generally disc-shaped and extends radially beyond the metalens 104 to form an outer annulus portion 1 14.
  • the body 102 may stabilize the subwavelength structures 108 suspended therein, and may also help maintain alignment of the metalens 104.
  • the metalens 104 may be foldable or bendable.
  • the implant 100 may be collapsed or folded (e.g. for insertion) and contained within a cartridge before implantation in the eye. During the implantation procedure, the implant 100 may be ejected from the cartridge into the eye, after which the implant 100 may unfold within the eye at a desired position for use, for example.
  • the cartridge may have a size that corresponds to the incision made in the eye.
  • the body 102 of the implant 100 may have a form“memory” position to which it returns when unfolding.
  • the subwavelength structures 108 in this example are nanofins. As will be apparent to a person skilled in the art, the size of the structures 108 are not shown to scale, but are substantially enlarged in Figure 1 for illustrative purposes. A person skilled in the art will also appreciate that in the metalens 104 will typically include many times more subwavelength structures 108 than are shown in Figure 1 (possibly on the order of one million structures 108 per square millimeter or more).
  • the diameter (d1 ) of the body 102 may be approximately 8 mm (although embodiments are not so limited), while each structure 108 may have height, width and/or thickness in the range of 10s to 100s of nanometers.
  • a nanofin-type subwavelength structure may be generally rectangular prism-shaped.
  • a nanofin sized to have a peak response at the wavelength of green light (532nm) may be 600nm high by 250nm wide by 95 nm thick (although embodiments are not limited to these particular dimensions).
  • the nanofins may, for example, be spaced approximately 600 nm apart.
  • the nanofins (or other subwavelength structures) may be arranged radially about the center axis 124 at various tilt angles relative to the radial direction. The separation between the structures 108 may similarly be in the range of nanometers.
  • the thickness of the metalens 104 may be on the order of microns, depending on the thickness of the substrate 106. Even including the body 102 that encapsulates the metalens 104, the overall thickness of the IOL implant 100 may be substantially less than conventional IOL implants, which typically have a thickness of approximately one millimeter or more.
  • the metalens may include multiple zones, with each zone having a respective distribution of subwavelength structures.
  • subwavelength structures in one zone may have one or more dimensions and/or distribution patterns that differ from one or more other zones.
  • Embodiments are not limited to a particular pattern, dimension, or distribution of the subwavelength structures.
  • the subwavelength structures 108 in the IOL implant 100 of Figure 1 are Ti02, although embodiments are not limited to Ti02 structures. Ti02 may be particularly suited for use in ophthalmic devices such as the IOL implant 100 of Figure 1 . Ti02 subwavelength structures 108 may be substantially lossless for light in the visible spectrum. Ti02 also has a high index of refraction (approximately 2.37 for 550 nm wavelength light), and metalenses using this dielectric may have high conversion efficiency.
  • conversion efficiency herein refers to the amount of visible light entering the system when compared to the amount in the final focal point. Losses may occur from reflection, scattering, absorption, diffraction, etc.
  • Mohammadreza Khorasaninejad, et al. referenced above disclose up to 86% actualized and 95% simulated conversion efficiency for Ti02 metalenses.
  • NA numerical aperture
  • Ti02 may be deposited on certain materials, atomic layer by layer by existing chip manufacturing technology.
  • the IOL implant 100 also includes optional haptics 1 16a and 1 16b, which may facilitate handling, centration and capsular bag stabilization of the IOL implant 100.
  • the haptics 1 16a and 1 16b are formed by a haptic spine 1 17.
  • the haptic spine 1 17 may be poly(methyl methacrylate) (PMMA), for example.
  • PMMA is more rigid than hydrophobic acrylic, but still somewhat flexible.
  • PMMA also has a“form memory” such that it may help stabilize the shape of the implant 100 while still allowing the implant 100 to be folded.
  • PMMA also has the advantage of being FDA approved. In some
  • the haptics 1 16a and 1 16b may be formed by multiple sections of PMMA rather than the continuous spine 1 17.
  • the implant may comprise a capsular tension ring (CTR) delivery system.
  • CTR capsular tension ring
  • a CTR system includes a foldable, injectable ring instead of PMMA haptics of the type shown in Figures 1 and 2.
  • the body 102 in this example also encapsulates the haptics 1 16a and 1 16b.
  • the haptics 1 16a and/or 1 16b may not be covered/encapsulated by the polymer body 102.
  • the overall length (L) of the IOL implant 100 (between ends 1 18a and 1 18b of the haptics 1 16a and 1 16b) in this example is approximately 13 mm. However, embodiments are not limited to a particular size or shape.
  • the IOL implant 100 may optionally be formed with a posterior convexity, which may enhance three-point fixation.
  • the substrate 106 of the metalens 104 may have a convex posterior face.
  • FIG 2 is a side view of the IOL implant 100 of Figure 1 .
  • the IOL implant 100 has an anterior face 120 and a posterior face 122. Again, the subwavelength structures 108 of the metalens 104 are not shown to scale for illustrative purposes.
  • the substrate 106 in this example is flat, but may have posterior convexity in other embodiments.
  • the hydrophobic acrylic body 102 encapsulates and stabilizes the metalens 104 and also covers the haptics 1 16a and 1 16b. As shown in Figure 2, the example haptics 1 16a and 1 16b in this embodiment are angled forward (about 10 degrees in this example). The haptics 1 16a and 1 16b may provide three- point fixation.
  • the center axis 124 is shown in Figure 2.
  • the metalens 104 extends radially about the center axis.
  • FIG. 3 is an enlarged perspective partial view of an example array 300 of nanofins 302 of a metalens.
  • the array 300 is only partially shown and extends beyond the stippled line border of Figure 3.
  • Similar nanofin arrays are shown by M. Khorasaninejad et al.“Super-Dispersive Off- Axis Meta-Lenses for Compact High Resolution Spectroscopy” Nano Lett. 2016, 16, 3732-3737, the entire content of which is incorporated by reference.
  • the nanofins 302 are generally rectangular-prism-shaped extensions from a substrate (not visible).
  • the subwavelength structures 108 of the IOL implant 100 shown in Figures 1 and 2 may be in a form similar to the nanofins 302 shown in Figure 3.
  • the array 300 may be representative of a small portion of the metalens 104 in Figures 1 and 2.
  • embodiments are not limited to the particular arrangement of nanofins shown in Figure 3.
  • the specific arrangement/pattern of the subwavelength structures may vary and is dependent upon the desired refractive outcome.
  • Embodiments are not limited to any particular configuration of the subwavelength structures.
  • an eye may be measured pre-operatively (e.g. by ultrasound or laser biometry).
  • the measurement may determine, for example, the corneal curvature, the anterior chamber depth, the axial length to the retina, and/or, depending on the type of IOL implant, the positioned refractive index of the IOL implant to be inserted.
  • a dioptric strength of the IOL may be calculated based on the eye measurement. For example, for a given eye, a lens from a first manufacture may require a dioptic strength of 21 5D to achieve emmetropia. For a second lens manufacturer, a dioptic strength of 22.5D may be required for the same eye.
  • Computer software may then be used to determine the dimensions and arrangement of the subwavelength structures based on the requirements obtained as a function of the eye measurement process.
  • One example of suitable software is LumericalTM simulation software.
  • the software may, for example, define the subwavelength pattern/arrangement to achieve the equivalent focal point to the refractive equivalent dioptric strength (21 5D or 22.5D in this example). This may be equivalent of traditional convex, concave, astigmatic (toric) or multifocal configurations. Flowever, the variable in lens configuration is not curvature (as for refractive lenses) but rather the height, width, tilt and separation of the subwavelength structures to achieve the same focus.
  • a metalens with the particular configuration determined by the LumericalTM computer simulation software may then be fabricated. Again, it is to be understood that embodiments are not limited to any particular arrangement or pattern of subwavelength structures, or to any method of determining the particular arrangement or pattern.
  • encapsulation of the metalens 104 and haptics 1 16a and 1 16b in the hydrophobic acrylic body 102 may provide biocompatibility and ocular immune sequestration. Since hydrophobic acrylic is conventionally used in ophthalmic devices, such as contact lenses and intraocular lens implants, the use of hydrophobic acrylic may, thus, facilitate regulatory approval of metalens-based ophthalmic devices described herein. As also mentioned above, Ti02 subwavelength structures may have antimicrobial properties, and other medical and dental devices use Ti02 for its non-toxicity, biocompatibility and biostability.
  • the implant 100 includes a 360 degree posterior optic epithelial lens barrier 125 (visible in Figure 2).
  • the barrier 125 has a 90 degree outer edge 126 in this embodiment and may inhibit lens epithelial migration and may reduce posterior capsular opacification.
  • the implant 100 may also include various other features not shown including, but not limited to, ultraviolet (UV) protection, blue filters, antireflection coatings, etc.
  • the implant may include vaulting.
  • Other embodiments may also include multifocal platforms.
  • the ophthalmic device may be a telescopic IOL implants.
  • the metalens-based ophthalmic devices described herein may not have designated front and back surfaces and may be reversible.
  • Figure 4 is a cross-sectional view of a human eye 200 showing a few example embodiments of ophthalmic devices 201 , 210, 220 and 230 are shown.
  • the ophthalmic device 201 is a contact lens including a polymer body 202 and a metalens (not visible) encapsulated therein within metalens zone 204.
  • the metalens zone 204 is visually represented by an array of ellipses in Figure 4, although it is to be understood that the metalens within zone 204 is typically significantly thinner than the zone 204 as shown.
  • the ellipses indicating the zone 204 are simply used to show the general region in which the metalens may be contained within the corresponding body 202.
  • the remaining ophthalmic devices 210, 220 and 230 in Figure 4 are similarly illustrated.
  • the body 202 is Silicone Hydrogel (SiHy) in this embodiment, but the body 202 may comprise other suitable materials (e.g. acrylic) in other embodiments.
  • SiHy materials such as the Hydra AcuvueTM series with high Oxygen Permeability (Dk) and Oxygen Transmissibility (Dk/t) may permit easy oxygen permeability/transmissibility with a higher modulus and rigidity.
  • a metalens-based device may be ultrathin and, being planar, may enhance the Dk and/or Dk/t.
  • SiHy material on a metalens platform might also be used as an intracorneal inlay after a femto stromal plane is created.
  • Ultrathin inlays with or without fenestrations may be more oxygen and nutrient transmissible and may be additive rather than subtractive.
  • a pocket in the cornea is created with a laser to receive a metalens inlay that is inserted surgically.
  • the metalens inlay is an“additive” procedure to correct a pre existing refractive error.
  • laser refractive surgery is a “subtractive” procedure that removes corneal tissue by laser-sculpting.
  • An example of laser refractive surgery is Small Incision Lenticule Extraction (SMILE), which is a subtractive procedure where a lenticule is cut with a laser and removed.
  • SMILE Small Incision Lenticule Extraction
  • an inlay only requires space enough to sit.
  • Another example of subtractive laser refractive surgery is Laser-Assisted in Situ Keratomileusis (LASIK).
  • LASIK Laser-Assisted in Situ Keratomileusis
  • One benefit of additive procedures, such as inserting an inlay is reversibility. For example, the inlay may be removed.
  • subtractive procedures such as laser refractive surgery are permanent.
  • the ophthalmic device 210 is a Femto Pocket Intracorneal inlay comprising a body 212 encapsulating a metalens (not shown) within metalens zone 214.
  • the body 212 in this example may be Silicone Hydrogel (SiHy), acrylic or another suitably biocompatible material.
  • Intracorneal inlays may also be referred to as intracorneal implants.
  • the ophthalmic device 220 is a Phakic Sulcus IOL implant comprising a body 222 encapsulating a metalens (not shown) within metalens zone 224.
  • the body 222 may, for example, be hydrophobic acrylic or another suitably biocompatible material.
  • Phakic lOL’s may be used for high refractive errors not correctable by LASIK or SMILE Conventional phakic IOL implants may have risks of infection
  • a metalens-based phakic IOL implant as disclosed herein, may be thinner and lighter than conventional implants, which in turn may reduce the likelihood and/or severity of such complications.
  • the ophthalmic device 230 is a
  • PCIOL implant comprising a body 232 encapsulating a metalens (not shown) within metalens zone 234.
  • the body 232 may, for example, be hydrophobic acrylic.
  • PC lOL’s by ST AAR and IOL Tech/Carl Zeiss Meditech may vault and cause angle closure/pupil block/PDS if too long. If too short, they may decenter or cause cataracts.
  • a metalens-based PC IOL (such as device 230) with hydrophobic acrylic encapsulation could utilize PMMA as a hapic or a CTR adapted for the sulcus with a central vault to protect the lens.
  • the metalenses of the devices 201 , 210, 220 and 230 may each be similar to the metalens 104 shown in Figures 1 and 2, including a substrate with a plurality of subwavelength structures thereon to interact with visible light.
  • Figures 5 and 6 are side-perspective views of an intraocular telescope 400 according to an embodiment.
  • the intraocular telescope 400 may be used to treat macular degeneration, for example.
  • the intraocular telescope 400 may be smaller than a conventional intraocular telescope.
  • the intraocular telescope 400 includes first and second portions 401 a and 401 b.
  • the first portion 401 a may be referred to as the “eyepiece lens” portion and the second portion 401 b may be referred to as the“objective lens” portion.
  • Each portion 401 a and 401 b includes a respective metalens 404a and 404b encapsulated in a respective polymer body 402a and 402b.
  • the first and second portions 401 a and 401 b are interconnected by first and second snap-in bridge pillars 405a and 405b.
  • the snap-in bridge pillars 405a and 405b fold to provide the folded position shown in Figure 6 and straighten to provide the extended position shown in Figure 5.
  • the intraocular telescope may, thus, be folded to a fixed focal distance between the eyepiece and objective lens.
  • IOL telescopes typically comprise a one-piece, large implantable device. This requires a large incision to implant when compared to other types of IOL implants.
  • the IOL telescope 400 in Figures 5 and 6 collapses or“spoons” the first and second portions 401 a and 401 b (in the folded position of Figure 6) for insertion.
  • the incision required to insert the IOL telescope 400 may be smaller (possibly even sutureless) compared to conventional IOL telescopes.
  • the snap-in bridge pillars 405a and 405b are sized to establish the desired separation between lenses when in their extended positions (shown in Figure 5).
  • the snap-in bridge pillars 405a and 405b may provide a fixed, non-adjustable focus.
  • an adjustment mechanism to allow adjustment of the separation may be used to provide multiple separation distances and/or autofocus functionality.
  • the intraocular telescope 400 is shown with optional PMMA haptics 416a and 416b.
  • the haptics 416a and 416b are similar to the haptics 1 16a and 1 16b in Figure 1 .
  • the haptics 416a and 416b may stabilize the IOL telescope 400 (e.g. within the capsular bag of the eye).
  • the haptics 416a and 416b are attached to the bridge pillars 405a and 405b respectively. Embodiments are not limited to any particular configuration of the haptics 416a and 416b.
  • the intraocular telescope 400 is shown with optional haptics 417a and 417b in an alternate configuration.
  • the haptics 417a and 417b are similar to the haptics 416a and 416b in Figure 5, but attached to the second portion 401 b of the intraocular telescope 400 rather than the bridge pillars 405a and 405b.
  • one or more haptics may be attached to the first portion 401 a of the intraocular telescope 400.
  • the ophthalmic device may be a keratoprosthesis.
  • a keratoprosthesis incorporating a metalens may have reduced weight, thickness and complexity compared to conventional designs.
  • Figure 7 is a flowchart of a method for making an ophthalmic device according to some embodiments.
  • a metalens is provided.
  • Providing the metalens may comprise manufacturing, purchasing or otherwise obtaining the metalens.
  • the metalens includes a plurality of dielectric subwavelength structures arranged on a substrate to interact with visible light.
  • the metalens may be similar to the metalens 104 of Figures 1 and 2, for example. An example method for making the metalens is described below with reference to Figure 8.
  • the metalens is encapsulated in a polymer body.
  • the polymer body may comprise hydrophobic acrylic, Silicone Flydrogel (SiHy) or any other suitable biocompatible material, as described above.
  • the device may be in the form of a contact lens, IOL implant, or other ophthalmic device (such as the devices 100, 201 , 210, 220, 230 or 400 of Figures 1 , 2 and 4 to 6).
  • the encapsulation may include a molding process.
  • technology similar to existing silicon chip manufacturing processes may be used or adapted for creating a metalens for an ophthalmic device.
  • An example EBL process for fabricating a metalens is described by Mohammadreza Khorasaninejad, et al. (2017), which is incorporated herein by reference.
  • FIG. 8 is a flowchart of a method for making a metalens for an ophthalmic device using an electron beam lithography (EBL) process according to some embodiments. Embodiments are not limited to the particular EBL process described below. The metalens may also be fabricated using a non-EBL process (e.g. UV lithography) in other embodiments.
  • EBL electron beam lithography
  • a polymer substrate is coated with a layer of resist.
  • the resist may, for example, be spin-coated on the substrate.
  • the resist in this example is an EBL resist such as ZEP 520A resist.
  • the thickness of the resist layer may determine the height of the nanostructures to be formed.
  • the resist is exposed by EBL, defining the pattern of the nanostructures in the resist.
  • EBL deep ultraviolet
  • lithography may be used to pattern the resist.
  • the pattern for the lithography step may generated using commercially available software (e.g. from Lumerical Inc.TM).
  • the resist is developed in o-xylene (e.g. 99% o- xylene). This step removes resist according to the lithographed pattern and leave holes or gaps that correspond to the geometry of the intended nanostructures. The remaining resist on the substrate at this stage may be referred to as“patterned” resist.
  • Ti02 is deposited onto the patterned resist.
  • the deposition may be performed by atomic layer deposition (ALD).
  • ALD atomic layer deposition
  • the Ti02 atomic layer deposition fills the gaps within the patterned resist to form subwavelength structures of the desired shape, diameter, height, tilt and spacing.
  • These subwavelength structures or short wavelength structures (SWS) may be customized to correct eye conditions, such as spherical and chromatic aberration.
  • simulations with Lumerical Inc.’sTM FDTD (finite difference time domain) solver programs may be used to create phase profiles for spherical, cylindrical or multifocal platforms, which may reduce or avoid the need to produce costly prototypes before manufacture.
  • the deposition of Ti02 may result in an excess Ti02 layer on top of the resist.
  • the excess layer of Ti02 over the resist is etched away.
  • the remaining resist is stripped.
  • the stripping may be performed using an overnight Remover-PG bath.
  • the remaining Ti02 structures on the substrate form the metalens, which may achieve a refractive outcome that is equivalent or better than a conventional lens.
  • Metalenses may be more efficient and have a higher numerical aperture than flat lenses made with diffractive optics because the wavelength scale ring structure of diffractive optics may degrade the phase profile of incident light.
  • the sub-wavelength scale of nanofin phase disrupters of some metalenses have been shown to achieve excellent diffraction limited focus.
  • the metalens-based technology described herein may allow related tools to be reduced in size. For example, smaller phako tips, folders, cartridges and handpieces as well as enhancing laser cataract platforms (e.g. Femto Laser Assisted Cataract Surgery (FLACS)) for micro incisional surgery may be made for use together with the metalens-based IOL implants described herein.
  • FLACS Femto Laser Assisted Cataract Surgery
  • Embodiments of the disclosure are not limited to the specific devices/implants shown in the drawings.
  • Other ophthalmic devices such as corneal inlays, may also incorporate one or more metalenses similar to the metalenses shown and described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Prostheses (AREA)

Abstract

Les dispositifs ophtalmiques sont utilisés pour traiter diverses affections oculaires. Ces dispositifs comprennent les implants de type lentille intraoculaire (LIO), les lentilles de contact, les télescopes intraoculaires et autres et comprennent généralement une ou plusieurs lentilles qui interagissent avec la lumière visible. Selon un aspect, la présente divulgation concerne un dispositif ophtalmique comprenant un corps polymère biocompatible et une méta-lentille, où la méta-lentille est encapsulée par le corps polymère. La méta-lentille comprend un substrat sensiblement transparent et une pluralité de structures à sous-longueur d'onde agencées sur le substrat selon un motif apte à interagir avec la lumière visible. Les structures à sous-longueur d'onde comprennent un matériau diélectrique tel que le dioxyde de titane.
PCT/CA2017/051529 2017-12-18 2017-12-18 Dispositif ophtalmique à méta-lentille et son procédé de fabrication WO2019119098A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/CA2017/051529 WO2019119098A1 (fr) 2017-12-18 2017-12-18 Dispositif ophtalmique à méta-lentille et son procédé de fabrication
CA3083612A CA3083612A1 (fr) 2017-12-18 2017-12-18 Dispositif ophtalmique a meta-lentille et son procede de fabrication
EP17935708.2A EP3727199A4 (fr) 2017-12-18 2017-12-18 Dispositif ophtalmique à méta-lentille et son procédé de fabrication

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2017/051529 WO2019119098A1 (fr) 2017-12-18 2017-12-18 Dispositif ophtalmique à méta-lentille et son procédé de fabrication

Publications (1)

Publication Number Publication Date
WO2019119098A1 true WO2019119098A1 (fr) 2019-06-27

Family

ID=66992441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2017/051529 WO2019119098A1 (fr) 2017-12-18 2017-12-18 Dispositif ophtalmique à méta-lentille et son procédé de fabrication

Country Status (3)

Country Link
EP (1) EP3727199A4 (fr)
CA (1) CA3083612A1 (fr)
WO (1) WO2019119098A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210115206A (ko) * 2020-03-12 2021-09-27 한국과학기술원 항균성 스마트 인공수정체
CN114402251A (zh) * 2019-07-29 2022-04-26 目立康株式会社 用于形成包括超构光学器件的眼科镜片的系统和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831640A1 (fr) * 2011-04-07 2012-10-18 Novartis Ag Structures optiques avec des caracteristiques de nanostructure et procedes d'utilisation et de fabrication
CA2846645A1 (fr) * 2013-03-15 2014-09-15 Johnson & Johnson Vision Care, Inc. Procedes pour lentilles ophtalmiques comportant des elements de metasurface
US9664817B1 (en) * 2011-09-08 2017-05-30 University Court Of The University Of St Andrews Flexible metamaterials of visible wavelengths
WO2017176921A1 (fr) * 2016-04-05 2017-10-12 President And Fellows Of Harvard College Méta-lentilles pour imagerie à résolution inférieure à la longueur d'onde

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831640A1 (fr) * 2011-04-07 2012-10-18 Novartis Ag Structures optiques avec des caracteristiques de nanostructure et procedes d'utilisation et de fabrication
US9664817B1 (en) * 2011-09-08 2017-05-30 University Court Of The University Of St Andrews Flexible metamaterials of visible wavelengths
CA2846645A1 (fr) * 2013-03-15 2014-09-15 Johnson & Johnson Vision Care, Inc. Procedes pour lentilles ophtalmiques comportant des elements de metasurface
WO2017176921A1 (fr) * 2016-04-05 2017-10-12 President And Fellows Of Harvard College Méta-lentilles pour imagerie à résolution inférieure à la longueur d'onde

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3727199A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114402251A (zh) * 2019-07-29 2022-04-26 目立康株式会社 用于形成包括超构光学器件的眼科镜片的系统和方法
EP4004638A4 (fr) * 2019-07-29 2023-11-08 Menicon Co., Ltd. Systèmes et procédés de formation de lentille ophtalmique comprenant des méta-optiques
KR20210115206A (ko) * 2020-03-12 2021-09-27 한국과학기술원 항균성 스마트 인공수정체
KR102363461B1 (ko) * 2020-03-12 2022-02-16 한국과학기술원 항균성 스마트 인공수정체

Also Published As

Publication number Publication date
EP3727199A1 (fr) 2020-10-28
EP3727199A4 (fr) 2021-07-14
CA3083612A1 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
US10912641B2 (en) Ophthalmic devices and methods
CA2712827C (fr) Lentille intraoculaire (iol) accommodative a aberration spherique dynamique
AU2010212408B2 (en) Multi-zonal monofocal intraocular lens for correcting optical aberrations
ES2634107T3 (es) Sistema para formar y modificar lentes y lentes formadas por el mismo
US9545303B2 (en) Ocular mask having selective spectral transmission
JP2020022791A (ja) プロテーゼ水晶体嚢およびその挿入方法
EP2407816A1 (fr) Lentilles intraoculaires multifocale à diffraction zonale
US20130238091A1 (en) Masked ocular device for implantation adjacent to an intraocular lens
JP2007319685A (ja) 眼内レンズ
JP4931932B2 (ja) 多焦点の補綴およびそれを使用し製造する方法
CN111200992A (zh) 复合光可调眼内透镜
WO2006067255A1 (fr) Lentille intraoculaire permettant d'achromatiser l'oeil et de reduire ses aberrations
EP2207502B1 (fr) Lentille ophtalmique photorefractive à multiples éléments
Zeng et al. Advances and challenges of intraocular lens design
EP3727199A1 (fr) Dispositif ophtalmique à méta-lentille et son procédé de fabrication
US20170304047A1 (en) Intraocular lens customized for astigmatism or combined astigmatism and presbyopia
EP2820465A2 (fr) Élément optique commutable réfractant-diffractant
RU2785137C2 (ru) Интраокулярные линзы, имеющие смещенную вперед оптическую конструкцию
Werner et al. Foldable intraocular lenses
NL2027301B1 (en) Mechanical means for accommodative intraocular lens
WO2002094131A2 (fr) Lentilles intra-oculaires a faible reflet de surface
Nordan et al. The Vision Membrane
Morris et al. Diffractive optics solution for phakic intraocular lenses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17935708

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3083612

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017935708

Country of ref document: EP

Effective date: 20200720